Volume 146, Issue 4, Pages 941-949.e2 (April 2014) Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease Mark T. Osterman, William J. Sandborn, Jean-Frederic Colombel, Anne M. Robinson, Winnie Lau, Bidan Huang, Paul F. Pollack, Roopal B. Thakkar, James D. Lewis Gastroenterology Volume 146, Issue 4, Pages 941-949.e2 (April 2014) DOI: 10.1053/j.gastro.2013.12.025 Copyright © 2014 AGA Institute Terms and Conditions
Figure 1 (A) Risk of malignancies excluding NMSC with adalimumab (ADA) monotherapy or combination therapy compared with the general population. (B) Risk of NMSC with ADA monotherapy or combination therapy compared with the general population. IMM, immunomodulator. Gastroenterology 2014 146, 941-949.e2DOI: (10.1053/j.gastro.2013.12.025) Copyright © 2014 AGA Institute Terms and Conditions